FocalTherics (NASDAQ:FOCL) CEO Buys $99,750.00 in Stock

FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes purchased 21,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $4.75 per share, with a total value of $99,750.00. Following the completion of the purchase, the chief executive officer owned 626,649 shares in the company, valued at approximately $2,976,582.75. This trade represents a 3.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

FocalTherics Price Performance

NASDAQ FOCL opened at $4.76 on Monday. The company’s 50-day simple moving average is $5.39. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The stock has a market cap of $178.40 million, a price-to-earnings ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. As a group, equities research analysts anticipate that FocalTherics will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Rock Springs Capital Management LP increased its stake in FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after buying an additional 91,500 shares in the last quarter. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter valued at about $2,623,000. Leonteq Securities AG bought a new position in shares of FocalTherics in the fourth quarter worth about $313,000. Kovack Advisors Inc. bought a new position in shares of FocalTherics in the fourth quarter worth about $53,000. Finally, Lido Advisors LLC purchased a new stake in shares of FocalTherics during the first quarter worth about $40,000. Institutional investors own 62.74% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 price target on shares of FocalTherics in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.75.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.